查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1807535

果凍市場按產品類型、材料類型、吸收性、應用和最終用戶分類－2025-2030 年全球預測

Biosurgery Market by Product Type, Material Type, Resorbability, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計 2024 年果凍市場價值將達到 171.5 億美元，2025 年成長至 185.8 億美元，複合年成長率為 8.48%，到 2030 年將達到 279.6 億美元。

主要市場統計數據
基準年2024年 171.5億美元
預計2025年 185.8億美元
預測年份 2030 279.6億美元
複合年成長率（%） 8.48%

果凍已成為現代醫療保健的關鍵領域，它整合生物活性材料，用於支持各種外科手術中的組織修復、止血和粘連。微創手術需求的不斷成長，加上生物材料科學的進步，推動該領域走在技術創新的前沿。相關人員正在應對一個動態的環境，其特點是法律規範不斷演變、成本限制日益增加，以及需要在日益複雜的患者群體中證明臨床療效。

果凍的創新步伐得益於材料科學家、工程師和臨床專家之間的跨學科合作，他們致力於最佳化性能和安全性。將新型膠原蛋白、纖維蛋白和合成基質轉化為可擴展的產品需要嚴格的檢驗，並與現有的外科工作流程進行週詳的整合。同時，監管機構正在完善途徑，以平衡病人安全和及時獲取，鼓勵製造商積極參與對話並提供證據。

本執行摘要全面闡述了塑造果凍市場的變革力量，包括技術突破、政策發展以及醫療保健提供者優先事項的轉變。它還闡明了近期關稅調整的影響，剖析了產品類型、材料、可吸收性特徵、臨床用途和最終用戶環境等核心細分維度，並揭示了細緻入微的區域動態。讀者將獲得關於競爭定位、夥伴關係機會以及未來關鍵決策點的策略清晰資訊。

繪製推動果凍創新和重塑全球醫療保健產業競爭格局的模式轉移

近年來，隨著先進的止血劑、生物黏合劑和組織移植技術的出現，果凍經歷了一場顛覆性的變革，這些技術提供了卓越的生物相容性和動態精度。纖維蛋白基密封劑和合成聚合物的創新為有效止血和組織再生開闢了新的途徑。此外，多學科研究舉措正在推動下一代複合材料的開發，這些複合材料整合了抗菌和生長因子功能，以簡化術後恢復。

評估2025年美國關稅調整對生物外科供應果凍、成本結構和策略採購實務的連鎖反應

美國當局實施的2025年修訂關稅表，為從國際供應商採購的生物外科材料和設備引入了新的成本維度。這些調整加強了對進口價格的審查，迫使製造商重新評估其供應商選擇和供應鏈架構。因此，採購團隊正在探索各種採購模式，例如近岸外包和區域合作，以穩定投入成本並緩解全球貿易中斷造成的波動。

確定核心細分框架，確定果凍產品、材料、可吸收性、應用和最終用戶概況的多樣化途徑

產品類型的分析顯示，止血劑、封閉劑和黏合劑以及組織移植物的發展軌跡各不相同。止血劑不斷發展，吸收動力學得到改善，給藥方式也更具客製化，以應對高風險手術中的出血挑戰。封閉劑和黏合劑的配方兼具強大的黏合強度和生物相容性的載體系統，使其受益匪淺。組織移植物，包括細胞基質和細胞化結構，正在不斷改進，以改善整個外科領域的整合和功能恢復。

解讀影響美洲、中東和非洲以及亞太地區果凍成長軌跡的區域趨勢

在美洲，對醫療基礎設施的大力投資以及對微創手術的關注正在推動市場成長。北美的監管支持和報銷框架正在推動高階生物外科產品的普及，而拉丁美洲市場則正透過有針對性的官民合作關係和能力建設舉措蓬勃發展。這種區域多樣性為製造商創造了機會，他們可以根據不同的資源環境和患者可及性因素來客製化產品組合。

主要企業的策略性舉措和創新管道：尖端解決方案和合作夥伴關係，開拓競爭前沿

領先的果凍公司正在推行差異化策略，以保持競爭優勢。一些公司優先收購利基技術公司，以增強產品平臺，並累積新型生物材料和先進輸送系統的專業知識。另一些公司則投入資源進行內部研發，並建立專門的研發中心，探索下一代複合材料和生物活性支架。與學術機構和受託研究機構的合作也促進了探索性研究，為未來的產品上市提供支援。

為行業領導者提供實用建議，以避免中斷、利用技術進步並確立果凍市場的領導地位

投資於適應性強的供應鏈策略對於企業應對不斷變化的貿易環境至關重要。建立多條採購管道，包括區域製造中心和合格的合約合作夥伴，可以緩解價格波動和物流瓶頸。主動與海關部門和認證機構溝通，也可以簡化進口流程，避免代價高昂的延誤。在採購框架中建立彈性，可以幫助企業保障業務連續性，並保護利潤率免受未來地緣政治波動的影響。

嚴格的多方法調查方法的詳細資訊，該方法結合了主要見解、二次分析和定量模型，揭示了果凍市場的真實本質

本研究整合了多方法研究框架，結合主要相關人員訪談、二手文獻分析和量化建模，全面涵蓋果凍領域。透過與外科醫生、採購專家、監管專家和產品經理的深入交流，我們獲得了關於未滿足需求、創新驅動力和應用障礙的第一手觀點。同時，我們也對已發表的臨床試驗、專利申請和政策白皮書進行了系統性回顧，以豐富研究背景，並促進定性資料與文獻證據的三角檢驗。

彙編關鍵發現和策略結論，為不斷發展的果凍系統中的相關人員闡明前進的道路

綜上所述，本摘要重點分析描繪了果凍領域在快速技術創新與經濟力量轉變交會的景象。先進的材料和專用輸送系統正在重新定義護理標準，而資費調整和不斷變化的法規既帶來了機遇，也帶來了限制。透過供應鏈多元化、策略夥伴關係和敏捷開發流程積極適應這些動態的相關人員，將最有能力塑造外科介入的未來發展軌跡。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 擴展再生細胞治療平台與生物外科基質相結合用於慢性傷口管理
  • 增加重組生長因子類止血劑在消化器官系統手術中的監管核准
  • 生醫材料Start-Ups與領先醫療技術公司擴大合作，加速新型密封劑的開發
  • 針對多重抗藥性病原體的下一代抗菌生物可吸收縫合線的開發
  • 透過將3D生物列印技術與生物外科支架結合來加速組織再生
  • 在機器人手術中使用微創止血劑減少術中出血併發症
  • 將人工智慧工具整合到果凍中，以預測患者的出血風險並最佳化藥物選擇。
  • 推出可在緊急創傷情況下快速部署的照護現場凍乾生物止血劑
  • 成本控制壓力促使人們採用合成生物外科黏合劑取代傳統的纖維蛋白膠
  • 透過 3D 列印工作流程，實現具有患者專用支架的可客製化生物外科植入

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第 8 章：果凍市場（依產品類型）

  • 止血劑
  • 密封劑和黏合劑
  • 組織移植

第9章果凍市場（依材料類型）

  • 膠原蛋白蛋白基
  • 纖維蛋白基
  • 明膠基
  • 合成

第 10 章：果凍市場吸收

  • 不可吸收
  • 吸收性
    • 完全可吸收
    • 部分可吸收

第 11 章果凍市場（按應用）

  • 心血管外科
    • 心臟繞道手術
    • 閥門維修
  • 一般外科
    • 疝氣修補術
    • 修復傷口
  • 微創手術
    • 內視鏡檢查
    • 腹腔鏡
  • 開放性手術
  • 整形外科
    • 關節重建
    • 脊椎融合手術

第 12 章果凍市場（依最終使用者）

  • 門診手術中心
  • 醫院
  • 專科診所
    • 牙醫診所
    • 眼科診所

第 13 章：美洲果凍市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

第 14 章歐洲、中東和非洲的果凍市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

第 15 章：亞太果凍市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第16章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Advanced Medical Solutions Group plc
    • Artivion, Inc.
    • B. Braun Melsungen AG
    • Baxter International Inc.
    • Becton, Dickinson and Company
    • BioCer Entwicklungs-GmbH
    • Boston Scientific Corporation
    • Cardinal Health, Inc.
    • Corza Medical GmbH
    • CryoLife, Inc.
    • CSL Limited
    • Hemostasis, LLC
    • Integra LifeSciences Holdings Corporation
    • Johnson & Johnson
    • Kuros Bioscience AG
    • Medtronic plc
    • Pfizer Inc.
    • RTI Surgical, Inc.
    • Samyang Holdings Corporation
    • Sanofi SA
    • Smith & Nephew plc
    • Stryker Corporation
    • Teleflex Incorporated
    • Tissue Regenix Ltd
    • Vivostat A/S

第17章 研究人工智慧

第18章 研究統計

第19章 研究聯絡人

第20章 研究報導

第21章 附錄

Product Code: MRR-AD36CD8982F7

The Biosurgery Market was valued at USD 17.15 billion in 2024 and is projected to grow to USD 18.58 billion in 2025, with a CAGR of 8.48%, reaching USD 27.96 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 17.15 billion
Estimated Year [2025] USD 18.58 billion
Forecast Year [2030] USD 27.96 billion
CAGR (%) 8.48%

Biosurgery has emerged as a pivotal domain within modern healthcare, integrating biologically active materials to support tissue repair, hemostasis, and adhesion in a range of surgical interventions. The growing demand for minimally invasive procedures, coupled with advances in biomaterials science, has propelled this field to the forefront of innovation. Stakeholders are navigating a dynamic environment characterized by evolving regulatory frameworks, heightened cost constraints, and the necessity to demonstrate clinical efficacy across increasingly complex patient populations.

The pace of innovation in biosurgery is being accelerated by cross-disciplinary collaboration among material scientists, engineers, and clinical specialists seeking to optimize performance and safety profiles. Translation of novel collagen, fibrin, and synthetic matrices into scalable products requires rigorous validation and thoughtful integration with existing surgical workflows. Concurrently, regulatory bodies are refining pathways to balance patient safety with timely access, encouraging manufacturers to engage in proactive dialogue and evidence generation.

This executive summary presents a cohesive exploration of the transformative forces shaping the biosurgery market, encompassing technological breakthroughs, policy developments, and shifting provider priorities. It articulates the implications of recent tariff adjustments, dissects core segmentation dimensions across product types, materials, resorbability characteristics, clinical applications, and end user contexts, and surfaces nuanced regional dynamics. Readers will gain strategic clarity on competitive positioning, partnership opportunities, and critical decision points ahead.

Mapping the Paradigm Shifts Driving Biosurgery Innovations and Reconfiguring Competitive Landscapes across Global Healthcare Sectors

In recent years, biosurgery has undergone paradigm-defining transformations driven by the emergence of advanced hemostatic agents, bioadhesives, and tissue graft technologies that offer superior biocompatibility and mechanistic precision. Innovations in fibrin-based sealants and synthetic polymers have unlocked new avenues for effective bleeding control and tissue regeneration. Moreover, multidisciplinary research initiatives are fueling the development of next-generation composites that integrate antimicrobial and growth factor functionalities to streamline postoperative recovery.

Simultaneously, the proliferation of minimally invasive and robotic-assisted techniques has elevated expectations for device design, demanding materials that adhere reliably within constrained working spaces. Surgeons are increasingly seeking solutions that combine ease of deployment with robust performance under physiological stress. This shift is catalyzing partnerships between instrument developers and biomaterial manufacturers aiming to deliver integrated systems that enhance precision, reduce operative times, and minimize patient trauma.

Looking ahead, the convergence of digital health platforms with biosurgery promises to redefine procedural planning, intraoperative guidance, and postoperative monitoring. Data-driven insights derived from real-world evidence studies are informing iterative product refinements, while artificial intelligence algorithms are being explored to predict patient-specific outcomes. These collective advancements are set to elevate biosurgical interventions, fostering a more proactive and personalized approach to tissue repair and hemostasis.

Assessing the Ripple Effects of United States Tariff Adjustments on Biosurgery Supply Chains, Cost Structures, and Strategic Sourcing Practices in 2025

The implementation of revised tariff schedules by United States authorities in 2025 has introduced a new cost dimension for biosurgical materials and devices sourced from international suppliers. These adjustments have heightened scrutiny on import pricing and compelled manufacturers to reevaluate both vendor selection and supply chain architecture. As a result, procurement teams are exploring diversified sourcing models, including nearshoring and regional partnerships, to stabilize input costs and mitigate volatility associated with global trade disruptions.

Beyond direct cost implications, the tariff changes have influenced global competitive dynamics, as domestic producers of hemostats, sealants, and grafts experience a relative advantage in their home markets. International companies are contemplating strategic investments in local manufacturing facilities or contractual alliances to preserve market access and maintain optimal lead times. Such moves underscore a broader trend toward supply chain resilience informed by geopolitical sensitivities and regulatory compliance mandates.

In parallel, tariffs have prompted manufacturers to intensify value engineering efforts, seeking to optimize formulations and reduce reliance on high-cost raw materials without compromising efficacy. Collaborative research agreements and joint ventures are gaining traction as a means to share development costs and expedite the co-creation of innovative products. Ultimately, these strategic adaptations aim to safeguard profitability while ensuring that patients continue to benefit from state-of-the-art biosurgical technologies.

Unveiling Core Segmentation Frameworks Illuminating Diversification Paths in Biosurgery Product Offerings, Materials, Resorbability, Applications, and End User Profiles

Analysis of product categories reveals distinct trajectories for hemostats, sealants and adhesives, and tissue grafts. Hemostatic agents continue to evolve with enhanced absorption kinetics and customizable delivery formats that address bleeding challenges in high-risk procedures. Sealants and adhesives are benefiting from formulations that combine robust bonding strength with biocompatible carrier systems. Tissue graft offerings, including acellular matrices and cellularized constructs, are being refined to improve integration and functional recovery across surgical disciplines.

Material innovations are driving differentiation across collagen-based, fibrin-based, gelatin-based, and synthetic constructs. Collagen matrices are prized for their natural biocompatibility and structural support, while fibrin-derived sealants capitalize on endogenous clotting cascades to reinforce hemostasis. Gelatin-based platforms offer versatile gelation properties that can be tuned for targeted applications, and synthetic polymers provide consistent performance characteristics and reduced immunogenicity. Each material class is undergoing iterative enhancements aimed at optimizing mechanical resilience and degradation profiles.

Resorbability characteristics play a critical role in clinical decision making, with nonresorbable options favored when long-term scaffold stability is required, and resorbable alternatives increasingly adopted to minimize foreign body presence. Fully resorbable materials degrade completely over a predetermined timeframe, supporting temporary support before safe clearance, while partially resorbable systems combine enduring frameworks with degradable components to balance structural needs with eventual absorption. This nuanced spectrum enables tailored therapeutic strategies across patient populations.

Application-specific segmentation underscores the importance of matching device properties to procedural requirements. Cardiovascular surgeries, including bypass operations and valve repairs, demand high-tensile strength adhesives and leak-resistant matrices. General surgical contexts such as hernia repair and wound management leverage lightweight scaffolds and malleable sealants for tissue approximation. Minimally invasive approaches, whether endoscopic or laparoscopic, call for delivery mechanisms compatible with narrow lumens. Orthopedic interventions, spanning joint replacement and spinal fusion, require load-bearing grafts. End user settings vary from ambulatory surgery centers to tertiary hospitals and specialty clinics in dental and ophthalmology practices.

Deciphering Regional Trends Shaping Biosurgery Growth Trajectories across the Americas, Europe Middle East & Africa, and the Asia-Pacific Domain

In the Americas, market growth is being driven by robust investment in healthcare infrastructure and a strong emphasis on minimally invasive procedures. North American regulatory support and reimbursement frameworks are encouraging adoption of premium biosurgical products, while Latin American markets are emerging through targeted public-private partnerships and capacity-building initiatives. This regional diversity presents opportunities for manufacturers that can tailor their portfolios to address varying resource environments and patient access considerations.

Europe, Middle East, and Africa represent a heterogeneous landscape where established Western European markets coexist with evolving economies across the Middle East and North Africa. In Western Europe, cost-containment pressures and rigorous clinical guidelines are prompting value-based adoption of biosurgical solutions. Simultaneously, the Gulf Cooperation Council countries are investing heavily in advanced medical facilities, creating demand for cutting-edge hemostatic and regenerative devices. Market entrants that navigate complex regulatory matrices and foster local collaborations are well positioned to capitalize on this spectrum.

Asia-Pacific is characterized by dynamic growth fueled by expanding healthcare access, rising surgical volumes, and government initiatives to fortify domestic manufacturing capabilities. Established markets such as Japan and Australia demand high-quality, certified products, whereas emerging economies in Southeast Asia and the Indian subcontinent are seeking affordable yet effective biosurgical interventions. Strategic alliances and technology transfer agreements are enabling global players to penetrate these markets, while regional innovators are advancing homegrown solutions tailored to local clinical needs.

Highlighting Strategic Moves and Innovation Pipelines among Leading Biosurgery Companies Forging the Competitive Frontier with Cutting-Edge Solutions and Collaborations

Leading players in the biosurgery arena are pursuing differentiated strategies to maintain competitive advantage. Some have prioritized acquisitions of niche technology firms to bolster their product pipelines, acquiring expertise in novel biomaterials and advanced delivery systems. Others are channeling resources into in-house R&D, establishing dedicated innovation centers to explore next-generation composites and bioactive scaffolds. Collaborations with academic institutions and contract research organizations are also fueling exploratory studies that underpin future product launches.

In addition to internal development, strategic partnerships are reshaping the ecosystem, with some companies entering co-development agreements to streamline regulatory pathways and share commercial risks. Joint ventures with regionally specialized manufacturers are enabling optimized production footprints and faster market access. Meanwhile, smaller, agile firms are carving distinct market positions by concentrating on adjacent therapeutic niches and demonstrating clinical superiority through targeted investigator-initiated trials. These varied approaches are collectively enriching the innovation pipeline.

Competitive dynamics are further influenced by concerted efforts to expand into new geographic territories and clinical segments. Entities with strong distribution networks in upstream specialties are branching into complementary areas, leveraging existing relationships to cross-sell biosurgical offerings. Simultaneously, investment in digital marketing and educational initiatives is equipping healthcare professionals with the knowledge required to adopt advanced technologies. These strategic maneuvers underscore a broader trend toward integrated solutions that transcend traditional product silos.

Empowering Industry Leaders with Pragmatic Recommendations to Navigate Disruption, Leverage Technological Advancements, and Cement Market Leadership in Biosurgery

Investing in adaptive supply chain strategies will be imperative for companies seeking to navigate the evolving trade environment. Establishing multiple sourcing lanes, including regional manufacturing hubs and qualified contract partners, can alleviate price unpredictability and logistical bottlenecks. Proactive engagement with customs authorities and certification bodies will also streamline import processes and prevent costly delays. By building resilience into procurement frameworks, organizations can safeguard operational continuity and protect profit margins against future geopolitical fluctuations.

Prioritizing innovation through cross-functional collaboration can accelerate the translation of novel biomaterials into market-ready solutions. Creating interdisciplinary teams that bring together clinical advisors, engineering specialists, and regulatory affairs experts fosters holistic product development and reduces time to market. In parallel, adopting an agile methodology for iterative design and validation allows for rapid refinement based on user feedback and real-world performance data. This approach ensures that new offerings consistently meet evolving clinician and patient needs.

Expanding strategic footprint within key regions requires tailored commercialization blueprints that reflect local reimbursement dynamics and clinical practices. Companies should invest in market intelligence and stakeholder mapping to identify high-impact entry points and partnership prospects. Cultivating relationships with leading healthcare professionals and opinion leaders can accelerate trial adoption and generate credible evidence to support broader uptake. Through targeted educational initiatives and value demonstration programs, firms can establish sustainable competitive moats in diverse geographies.

Enhancing digital capabilities and data analytics is vital for unlocking deeper insights into procedural outcomes and customer preferences. Implementing robust feedback loops via digital platforms enables continuous product improvement and personalized engagement. Moreover, leveraging predictive analytics to identify emerging clinical trends and procurement patterns empowers commercial teams to proactively position their portfolios. By aligning digital transformation efforts with core business objectives, industry leaders can capitalize on untapped growth opportunities within the biosurgery domain.

Detailing a Rigorous Multimethod Research Methodology Integrating Primary Insights, Secondary Analysis, and Quantitative Modeling to Illuminate Biosurgery Market Realities

This study integrates a multimethod research framework combining primary stakeholder interviews, secondary literature analysis, and quantitative modeling to ensure comprehensive coverage of the biosurgery landscape. In-depth conversations with surgeons, procurement specialists, regulatory experts, and product managers provided first-hand perspectives on unmet needs, innovation drivers, and adoption barriers. Concurrently, a systematic review of published clinical trials, patent filings, and policy white papers enriched the contextual foundation and facilitated triangulation of qualitative inputs with documented evidence.

Quantitative modeling efforts employed robust statistical techniques and sensitivity analyses to explore relationships between key variables such as material properties, procedural volumes, and cost parameters. Data inputs were sourced from peer-reviewed journals, global health organization reports, and public regulatory databases. Regional market maps were constructed using a geospatial approach, enabling visualization of demand concentrations and growth corridors. This quantitative backbone was iteratively validated against primary insights to refine accuracy and coherence.

Quality assurance protocols were implemented throughout the research process, including peer review of analytical outputs, data integrity checks, and validation workshops with external subject matter specialists. Each phase of the methodology adhered to established best practices in market and clinical research, ensuring that conclusions are grounded in both empirical rigor and real-world relevance. This comprehensive approach underpins the credibility of the findings and recommendations presented in this executive summary.

Synthesizing Crucial Findings and Strategic Conclusions to Illuminate the Path Forward for Stakeholders in the Evolving Biosurgery Ecosystem Worldwide

Collectively, the analyses highlighted in this summary illustrate a biosurgery sector at the intersection of rapid technological innovation and shifting economic forces. Advanced materials and application-specific delivery systems are redefining standards of care, while tariff adjustments and regulatory evolutions introduce both opportunities and constraints. Stakeholders who proactively adapt to these dynamics-through supply chain diversification, strategic partnerships, and agile development processes-will be best positioned to shape the future trajectory of surgical interventions.

The segmentation and regional assessments underscore a market characterized by granularity and heterogeneity, where success depends on nuanced understanding of material performance, procedure requirements, and local healthcare landscapes. Leading companies are aligning R&D pipelines with emerging clinical needs and forging collaborative models to accelerate commercial access. As data-driven methodologies and digital tools assume greater prominence, the capacity to generate and act upon actionable intelligence will differentiate market leaders from late adopters.

In sum, this executive summary offers a strategic compass for decision-makers seeking to navigate the complexities of the biosurgery ecosystem. By synthesizing critical insights related to technology trends, policy shifts, segmentation nuances, and competitive behaviors, it equips stakeholders with the clarity needed to make informed investment, development, and commercialization choices. The path forward will demand both visionary leadership and operational excellence to realize the full potential of biosurgical innovations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Expansion of regenerative cell therapy platforms combined with biosurgical matrices for chronic wound management
  • 5.2. Increasing regulatory approvals for recombinant growth factor based hemostats in gastrointestinal procedures
  • 5.3. Rising partnerships between biomaterial start ups and large medtech players to fast track novel sealants
  • 5.4. Development of next generation antimicrobial bioabsorbable sutures targeting multidrug resistant pathogens
  • 5.5. Integration of 3d bioprinting techniques with biosurgical scaffolds for accelerated tissue regeneration
  • 5.6. Adoption of minimally invasive hemostatic agents in robotic surgery to reduce perioperative bleeding complications
  • 5.7. Integration of artificial intelligence tools in biosurgery to predict patient bleeding risk and optimize agent selection
  • 5.8. Emergence of point of care lyophilized biologic hemostats for rapid deployment in emergency trauma care settings
  • 5.9. Cost containment pressures driving adoption of synthetic biosurgical adhesives over traditional fibrin sealants
  • 5.10. Shift towards customizable biosurgical implants with patient specific scaffolding via 3d printing workflows

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Biosurgery Market, by Product Type

  • 8.1. Introduction
  • 8.2. Hemostats
  • 8.3. Sealants & Adhesives
  • 8.4. Tissue Grafts

9. Biosurgery Market, by Material Type

  • 9.1. Introduction
  • 9.2. Collagen-Based
  • 9.3. Fibrin-Based
  • 9.4. Gelatin-Based
  • 9.5. Synthetic

10. Biosurgery Market, by Resorbability

  • 10.1. Introduction
  • 10.2. Nonresorbable
  • 10.3. Resorbable
    • 10.3.1. Fully Resorbable
    • 10.3.2. Partially Resorbable

11. Biosurgery Market, by Application

  • 11.1. Introduction
  • 11.2. Cardiovascular Surgery
    • 11.2.1. Bypass Surgery
    • 11.2.2. Valve Repair
  • 11.3. General Surgery
    • 11.3.1. Hernia Repair
    • 11.3.2. Wound Repair
  • 11.4. Minimally Invasive Surgery
    • 11.4.1. Endoscopic
    • 11.4.2. Laparoscopic
  • 11.5. Open Surgery
  • 11.6. Orthopedic Surgery
    • 11.6.1. Joint Replacement
    • 11.6.2. Spinal Fusion

12. Biosurgery Market, by End User

  • 12.1. Introduction
  • 12.2. Ambulatory Surgery Centers
  • 12.3. Hospitals
  • 12.4. Specialty Clinics
    • 12.4.1. Dental Clinics
    • 12.4.2. Ophthalmology Clinics

13. Americas Biosurgery Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Biosurgery Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Biosurgery Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Advanced Medical Solutions Group plc
    • 16.3.2. Artivion, Inc.
    • 16.3.3. B. Braun Melsungen AG
    • 16.3.4. Baxter International Inc.
    • 16.3.5. Becton, Dickinson and Company
    • 16.3.6. BioCer Entwicklungs-GmbH
    • 16.3.7. Boston Scientific Corporation
    • 16.3.8. Cardinal Health, Inc.
    • 16.3.9. Corza Medical GmbH
    • 16.3.10. CryoLife, Inc.
    • 16.3.11. CSL Limited
    • 16.3.12. Hemostasis, LLC
    • 16.3.13. Integra LifeSciences Holdings Corporation
    • 16.3.14. Johnson & Johnson
    • 16.3.15. Kuros Bioscience AG
    • 16.3.16. Medtronic plc
    • 16.3.17. Pfizer Inc.
    • 16.3.18. RTI Surgical, Inc.
    • 16.3.19. Samyang Holdings Corporation
    • 16.3.20. Sanofi SA
    • 16.3.21. Smith & Nephew plc
    • 16.3.22. Stryker Corporation
    • 16.3.23. Teleflex Incorporated
    • 16.3.24. Tissue Regenix Ltd
    • 16.3.25. Vivostat A/S

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. BIOSURGERY MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL BIOSURGERY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL BIOSURGERY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOSURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BIOSURGERY MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL BIOSURGERY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL BIOSURGERY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL BIOSURGERY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS BIOSURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS BIOSURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES BIOSURGERY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES BIOSURGERY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC BIOSURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC BIOSURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. BIOSURGERY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. BIOSURGERY MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. BIOSURGERY MARKET: RESEARCHAI
  • FIGURE 26. BIOSURGERY MARKET: RESEARCHSTATISTICS
  • FIGURE 27. BIOSURGERY MARKET: RESEARCHCONTACTS
  • FIGURE 28. BIOSURGERY MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. BIOSURGERY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOSURGERY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOSURGERY MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOSURGERY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOSURGERY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL BIOSURGERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOSURGERY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOSURGERY MARKET SIZE, BY HEMOSTATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOSURGERY MARKET SIZE, BY HEMOSTATS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOSURGERY MARKET SIZE, BY SEALANTS & ADHESIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOSURGERY MARKET SIZE, BY SEALANTS & ADHESIVES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOSURGERY MARKET SIZE, BY TISSUE GRAFTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOSURGERY MARKET SIZE, BY TISSUE GRAFTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOSURGERY MARKET SIZE, BY COLLAGEN-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOSURGERY MARKET SIZE, BY COLLAGEN-BASED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOSURGERY MARKET SIZE, BY FIBRIN-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOSURGERY MARKET SIZE, BY FIBRIN-BASED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOSURGERY MARKET SIZE, BY GELATIN-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOSURGERY MARKET SIZE, BY GELATIN-BASED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOSURGERY MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOSURGERY MARKET SIZE, BY SYNTHETIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOSURGERY MARKET SIZE, BY NONRESORBABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOSURGERY MARKET SIZE, BY NONRESORBABLE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOSURGERY MARKET SIZE, BY RESORBABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOSURGERY MARKET SIZE, BY RESORBABLE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOSURGERY MARKET SIZE, BY FULLY RESORBABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOSURGERY MARKET SIZE, BY FULLY RESORBABLE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOSURGERY MARKET SIZE, BY PARTIALLY RESORBABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOSURGERY MARKET SIZE, BY PARTIALLY RESORBABLE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIOSURGERY MARKET SIZE, BY BYPASS SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOSURGERY MARKET SIZE, BY BYPASS SURGERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL BIOSURGERY MARKET SIZE, BY VALVE REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOSURGERY MARKET SIZE, BY VALVE REPAIR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL BIOSURGERY MARKET SIZE, BY HERNIA REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOSURGERY MARKET SIZE, BY HERNIA REPAIR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL BIOSURGERY MARKET SIZE, BY WOUND REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOSURGERY MARKET SIZE, BY WOUND REPAIR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL BIOSURGERY MARKET SIZE, BY ENDOSCOPIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOSURGERY MARKET SIZE, BY ENDOSCOPIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL BIOSURGERY MARKET SIZE, BY LAPAROSCOPIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOSURGERY MARKET SIZE, BY LAPAROSCOPIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL BIOSURGERY MARKET SIZE, BY OPEN SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOSURGERY MARKET SIZE, BY OPEN SURGERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL BIOSURGERY MARKET SIZE, BY JOINT REPLACEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOSURGERY MARKET SIZE, BY JOINT REPLACEMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL BIOSURGERY MARKET SIZE, BY SPINAL FUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOSURGERY MARKET SIZE, BY SPINAL FUSION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL BIOSURGERY MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOSURGERY MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL BIOSURGERY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOSURGERY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL BIOSURGERY MARKET SIZE, BY DENTAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOSURGERY MARKET SIZE, BY DENTAL CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL BIOSURGERY MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOSURGERY MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 89. AMERICAS BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 91. AMERICAS BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 93. AMERICAS BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 95. AMERICAS BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 97. AMERICAS BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 107. AMERICAS BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 109. AMERICAS BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 111. AMERICAS BIOSURGERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS BIOSURGERY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 113. UNITED STATES BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. UNITED STATES BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 115. UNITED STATES BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. UNITED STATES BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 117. UNITED STATES BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 118. UNITED STATES BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 119. UNITED STATES BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 120. UNITED STATES BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 121. UNITED STATES BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 122. UNITED STATES BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED STATES BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED STATES BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED STATES BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED STATES BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED STATES BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED STATES BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 131. UNITED STATES BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 132. UNITED STATES BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 133. UNITED STATES BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 134. UNITED STATES BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 135. UNITED STATES BIOSURGERY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 136. UNITED STATES BIOSURGERY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 137. CANADA BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. CANADA BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 139. CANADA BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. CANADA BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 141. CANADA BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 142. CANADA BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 143. CANADA BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 144. CANADA BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 145. CANADA BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 146. CANADA BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 147. CANADA BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 148. CANADA BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 149. CANADA BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 150. CANADA BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 151. CANADA BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 152. CANADA BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 153. CANADA BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 154. CANADA BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 155. CANADA BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 156. CANADA BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 157. CANADA BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 158. CANADA BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 159. MEXICO BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. MEXICO BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 161. MEXICO BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. MEXICO BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 163. MEXICO BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 164. MEXICO BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 165. MEXICO BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 166. MEXICO BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 167. MEXICO BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 168. MEXICO BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 169. MEXICO BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 170. MEXICO BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 171. MEXICO BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 172. MEXICO BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 173. MEXICO BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 174. MEXICO BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 175. MEXICO BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 176. MEXICO BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 177. MEXICO BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. MEXICO BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 179. MEXICO BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 180. MEXICO BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 181. BRAZIL BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. BRAZIL BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 183. BRAZIL BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. BRAZIL BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 185. BRAZIL BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 186. BRAZIL BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 187. BRAZIL BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 188. BRAZIL BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 189. BRAZIL BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 190. BRAZIL BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 191. BRAZIL BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 192. BRAZIL BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 193. BRAZIL BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 194. BRAZIL BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 195. BRAZIL BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 196. BRAZIL BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 197. BRAZIL BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 198. BRAZIL BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 199. BRAZIL BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. BRAZIL BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 201. BRAZIL BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 202. BRAZIL BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 203. ARGENTINA BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. ARGENTINA BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 205. ARGENTINA BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. ARGENTINA BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 207. ARGENTINA BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 208. ARGENTINA BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 209. ARGENTINA BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 210. ARGENTINA BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 211. ARGENTINA BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. ARGENTINA BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 213. ARGENTINA BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 214. ARGENTINA BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 215. ARGENTINA BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 216. ARGENTINA BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 217. ARGENTINA BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 218. ARGENTINA BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 219. ARGENTINA BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 220. ARGENTINA BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 221. ARGENTINA BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. ARGENTINA BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 223. ARGENTINA BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 224. ARGENTINA BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 249. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 251. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 253. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 254. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 255. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 257. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 259. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 260. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 261. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 262. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 263. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 264. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 265. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 266. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 267. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 269. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 270. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 271. GERMANY BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. GERMANY BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 273. GERMANY BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. GERMANY BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 275. GERMANY BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 276. GERMANY BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 277. GERMANY BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 278. GERMANY BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 279. GERMANY BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 280. GERMANY BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 281. GERMANY BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 282. GERMANY BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 283. GERMANY BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 284. GERMANY BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 285. GERMANY BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 286. GERMANY BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 287. GERMANY BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 288. GERMANY BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 289. GERMANY BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. GERMANY BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 291. GERMANY BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 292. GERMANY BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 293. FRANCE BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. FRANCE BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 295. FRANCE BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. FRANCE BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 297. FRANCE BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 298. FRANCE BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 299. FRANCE BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 300. FRANCE BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 301. FRANCE BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 302. FRANCE BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 303. FRANCE BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 304. FRANCE BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 305. FRANCE BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 306. FRANCE BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 307. FRANCE BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 308. FRANCE BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 309. FRANCE BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 310. FRANCE BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 311. FRANCE BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. FRANCE BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 313. FRANCE BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 314. FRANCE BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 315. RUSSIA BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. RUSSIA BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 317. RUSSIA BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. RUSSIA BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 319. RUSSIA BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 320. RUSSIA BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 321. RUSSIA BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 322. RUSSIA BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 323. RUSSIA BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 324. RUSSIA BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 325. RUSSIA BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 326. RUSSIA BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 327. RUSSIA BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 328. RUSSIA BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 329. RUSSIA BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 330. RUSSIA BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 331. RUSSIA BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 332. RUSSIA BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 333. RUSSIA BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. RUSSIA BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 335. RUSSIA BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 336. RUSSIA BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 337. ITALY BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 338. ITALY BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 339. ITALY BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 340. ITALY BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 341. ITALY BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 342. ITALY BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 343. ITALY BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 344. ITALY BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 345. ITALY BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 346. ITALY BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 347. ITALY BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 348. ITALY BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 349. ITALY BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 350. ITALY BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 351. ITALY BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 352. ITALY BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 353. ITALY BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 354. ITALY BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 355. ITALY BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 356. ITALY BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 357. ITALY BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 358. ITALY BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 359. SPAIN BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 360. SPAIN BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 361. SPAIN BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 362. SPAIN BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 363. SPAIN BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 364. SPAIN BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 365. SPAIN BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 366. SPAIN BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)